JNJ-64264681 + JNJ-67856633

JNJ-64264681 + JNJ-67856633 is an investigational **oral combination therapy** for B-cell non-Hodgkin lymphoma (B-cell NHL) and chronic lymphocytic leukemia (CLL). JNJ-64264681 is a second-generation, irreversible covalent inhibitor of Bruton’s tyrosine kinase (BTK), a key protein in B cell receptor signaling that drives B-cell activation and survival. JNJ-67856633 (also known as safimaltib) is a first-in-class, orally bioavailable, allosteric inhibitor of MALT1 (mucosa-associated lymphoid tissue lymphoma translocation protein 1), a downstream effector of BTK in BCR/NF-κB pathway signaling. The combination aims to provide synergistic anti-tumor effects by dual inhibition of complementary signaling pathways in malignant B-cells, with the goal of overcoming resistance mechanisms and improving efficacy compared to monotherapies. Both drugs are being developed by Janssen for the treatment of B-cell NHL and CLL and are currently in early (Phase 1b) clinical trials[1][2][3][5][7][8][9].

Other names

safimaltib (for JNJ-67856633)